OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer	488
Issue Information	376
The economics of advanced and unresectable hepatocellular carcinoma	212
New standard of care for multiple myeloma?	155
Best of both worlds? Linking comprehensive and noncomprehensive cancer centers	155
MRI is more accurate than a PSMA PET/CT scan for prostate cancer diagnosis	133
Potential of circulating tumor DNA to refine immunotherapy	97
Serum of interleukin‐6 and procalcitonin as early diagnostic markers for the identification of poor hematopoietic reconstitution following allogeneic hematopoietic stem cell transplantation	88
Reply to “Enhancing the role of social work in managing cancer risks among LGBTQ+ populations” and “The urgency of systematically acquiring sexual orientation and gender identity data to ensure equity	73
	70
Accelerated approval of multiple myeloma therapies	70
Issue Information	68
Top advances of the year: Neoadjuvant immunotherapy in melanoma	65
	65
	64
Issue Information	63
Issue Information	63
	59
Implantable cardioverter defibrillators in people dying with cancer: A SEER‐Medicare analysis of ICD prevalence and association with aggressive end‐of‐life care	58
New test for detecting cervical adenocarcinoma	58
The Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (CISTO) study: Lessons learned about management and patient enrollment in a large, pragmatic, patient‐centere	56
Stopping immunotherapy after 2 years is practical in patients with advanced non–small cell lung cancer	55
Sharp rise in esophageal cancer and Barrett esophagus seen in middle‐aged people	55
Can we avoid thoracic radiotherapy in young females with Hodgkin lymphoma?	55
Dietary supplement use among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort Study	54

Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3‐tyrosine kinase domain mutations: Prognostic implications of NPM1 co‐mutation	50
Correction to “Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly”	49
Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53	49
Association between visceral adiposity index and cancer risk in the UK Biobank cohort	48
Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers	47
Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK‐positive advanced non–small cell lung cancer	47
Erratum to “Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation”	46
Erratum to “Chimeric antigen receptor–based immunotherapy in breast cancer: Recent progress in China”	46
Disparities in prostate cancer screening, diagnoses, management, and outcomes between Indigenous and non‐Indigenous men in a universal health care system	46
Erratum to “Incorporation of alemtuzumab into frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study”	45
Erratum to “Unhealthy lifestyle behaviors, overweight, and obesity among childhood cancer survivors in the Netherlands: A DCCSS LATER study”	45
Midlife baseline prostate‐specific antigen, velocity, and doubling time association with lethal prostate cancer and mortality	44
Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries	44
Redefining the “crown”: Approaching chemotherapy‐induced alopecia among Black patients with breast cancer	43
Multicenter study of pediatric Epstein‐Barr virus–negative monomorphic post solid organ transplant lymphoproliferative disorders	43
Development and validation of a machine‐learning–based pathomics nomogram for predicting recurrence of localized primary gastrointestinal stromal tumors after complete surgical resection: A retrospect	42
Characteristics of clinical trials of new oncology drugs approved in China	42